Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities
Researchers have identified new therapeutic vulnerabilities in microsatellite stable (MSS) colorectal cancer using a multiomic AI tool called iPhenMap. The study suggests that repurposing existing drugs could lead to more effective, personalized treatment options for patients.
Why it matters
This research offers a potential breakthrough for patients with advanced colorectal cancer who have limited treatment options.
An international study headed by scientists at RCSI University of Medicine and Health Sciences, and The Institute of Cancer Research, London, has identified potential new ways to treat microsatellite stable (MSS) colorectal cancer (CRC). The team integrated multiomic, single-cell, and clinical data from around 2,000 CRC tumors and developed an AI tool, iPhenMap, to create biological tumor maps.
The study uncovered vulnerabilities in these tumors and identified the drug combinations—including drugs already approved to treat other tumor types—that in vivo experiments in models indicated could be used to target CRC, potentially enabling more effective treatments. The researchers suggest that their results provide a clear roadmap for repurposing existing drugs and for new drug development to create more effective, personalized treatments for patients who currently have limited options.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in